2,400 AbbVie Inc. $ABBV Shares Purchased by Newman Dignan & Sheerar Inc.

Newman Dignan & Sheerar Inc. boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 57.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,547 shares of the company’s stock after buying an additional 2,400 shares during the quarter. Newman Dignan & Sheerar Inc.’s holdings in AbbVie were worth $1,713,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Benchmark Financial Wealth Advisors LLC boosted its position in AbbVie by 11.0% during the third quarter. Benchmark Financial Wealth Advisors LLC now owns 4,309 shares of the company’s stock worth $1,127,000 after purchasing an additional 428 shares in the last quarter. Cushing Capital Partners LLC purchased a new stake in shares of AbbVie during the third quarter worth approximately $242,000. Physician Wealth Advisors Inc. grew its holdings in shares of AbbVie by 11.3% during the third quarter. Physician Wealth Advisors Inc. now owns 1,531 shares of the company’s stock worth $401,000 after buying an additional 155 shares in the last quarter. Ironwood Financial llc grew its stake in AbbVie by 1.8% during the 3rd quarter. Ironwood Financial llc now owns 3,069 shares of the company’s stock valued at $803,000 after acquiring an additional 55 shares in the last quarter. Finally, Taylor Securities Services Inc. raised its holdings in AbbVie by 2.6% in the 3rd quarter. Taylor Securities Services Inc. now owns 2,267 shares of the company’s stock valued at $593,000 after acquiring an additional 57 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABBV. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. HSBC boosted their target price on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. UBS Group increased their price target on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a report on Tuesday, October 6th. Oppenheimer increased their price target on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Finally, Scotiabank lifted their price objective on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $278.07.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

AbbVie Trading Down 1.5%

Shares of ABBV opened at $284.63 on Thursday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $291.40. The firm has a market capitalization of $502.89 billion, a P/E ratio of 80.41, a P/E/G ratio of 1.32 and a beta of 0.24. The firm has a 50-day moving average price of $264.93 and a 200 day moving average price of $240.92.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the firm earned $2.97 earnings per share. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts predict that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.